What type of cancer treatment drug does adagrasib belong to?

Adagrasib is a targeted drug that is a KRAS G12C inhibitor and is mainly used to treat non-small cell lung cancer (NSCLC) with KRAS G12C mutations. KRAS gene mutations, especially KRAS G12C mutations, usually appear in various malignant tumors such as lung cancer and colorectal cancer, and are important factors leading to tumor occurrence and progression. Adagrasib targets the KRAS G12C mutated protein and prevents it from activating downstream signaling pathways, thereby inhibiting the growth and spread of cancer cells and has a good therapeutic effect.

Adagrasib is different from other targeted drugs in that its mechanism of action specifically targets the KRAS G12C mutation. This mutation usually keeps the KRAS protein in a continuously active state and promotes the proliferation of tumor cells. Adagrasib binds to the KRAS G12C mutated protein and inhibits its activity, thereby blocking the proliferation signals of cancer cells. Therefore, adagrasib is mainly used for patients with KRAS G12C mutation-positive lung cancer, especially those who have received other therapies but still have disease progression.

In terms of clinical application, adagrasib has demonstrated significant efficacy in multiple clinical trials. For patients with KRAS G12C mutated non-small cell lung cancer, adagrasib can effectively inhibit tumor growth and delay the progression of the disease. It provides a new treatment option, especially for those patients who have failed multiple chemotherapy or immunotherapy treatments. In addition, the side effects of adagrasib are relatively controllable. Common adverse reactions include fatigue, diarrhea and nausea, which can be tolerated by most patients.

The advantage of adagrasib is that it can accurately target the KRAS G12C mutation, reducing damage to normal cells, thereby reducing the side effects of treatment. Due to its strong targeting, adagrasib has become an effective drug for the treatment of KRAS G12C mutated lung cancer. However, before using adagrasib, patients must undergo genetic testing for the KRAS G12C mutation to ensure the suitability of the drug. Through accurate genetic testing, doctors can provide patients with the most suitable treatment plan and improve the effectiveness of treatment.

References：https://www.krazati.com/